U.K.'s Oxford BioMedica PLC and Bioverativ Inc. agreed to collaborate to develop and manufacture lentiviral vectors for treating hemophilia using gene therapy.
Lentiviral vectors are used in gene therapy to modify genes using lentivirus, a family of viruses responsible for diseases such as HIV.
Under the deal, Waltham, Mass.-based Bioverativ will pay Oxford BioMedica $5 million up front. Oxford BioMedica is also eligible to receive about $100 million in milestone payments, as well as undisclosed royalties on net sales of products arising from the deal.
The agreement also grants Bioverativ a license to Oxford BioMedica's lentiviral vector technology and access to the latter's industrial-scale manufacturing technology.
Bioverativ will fund process development and scale-up activities for its lentiviral vector hemophilia products. The two companies also agreed to put in place a clinical supply agreement for manufacturing the hemophilia products at Oxford BioMedica.